Ophthalmology and therapy · 2025
Post-market Surveillance Analysis of Refractive Data in Users of Delivery Tyro®, a Tyrosine-Releasing Contact Lens.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ponzin Diego, Fasolo Adriano, Montani Giancarlo, Bazzocchi Daniele
Аннотация
INTRODUCTION: Myopia is a growing public health concern, particularly among young individuals. Several pharmacological and optical interventions exist to slow its progression, yet each has limitations. In January 2021, Safilens introduced the Delivery Tyro® daily disposable contact lens, which releases hyaluronic acid, tamarind seed polysaccharide, and tyrosine, a dopamine precursor with antioxidative and cytoprotective properties.
METHODS: This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, - 2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro® lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro® users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.
RESULTS: Delivery Tyro® users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a - 0.04 D compared with the expected change of - 0.28 D from the reference control group (P < 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of - 0.25 D or less).
CONCLUSIONS: These findings support the hypothesis that Delivery Tyro® may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro® may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro® through controlled, randomized clinical trials is warranted.
METHODS: This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, - 2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro® lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro® users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.
RESULTS: Delivery Tyro® users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a - 0.04 D compared with the expected change of - 0.28 D from the reference control group (P < 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of - 0.25 D or less).
CONCLUSIONS: These findings support the hypothesis that Delivery Tyro® may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro® may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro® through controlled, randomized clinical trials is warranted.